

Factsheet

Name	InfectoPharm Arzneimittel und Consilium GmbH
Sector	Pharmaceutical industry
Type	Family-owned medium-sized company
Target markets	Pharmaceuticals for children (pediatrics) Dermatology ENT Difficult-to-treat infections in hospitals Over the counter (OTC) products
Core	Development and improvement of pharmaceuticals with medically proven active ingredients
Guiding principle	„Knowledge is Health“
USP	<i>consilium</i> service – consulting and training for physicians and other healthcare professionals in Germany
Headquarter	Heppenheim (Hesse), Germany
Founded in	1988
Founder	Dr. Manfred Zöller† and Monika Zöller
Management Board	Philipp Zöller – Chief Executive Business Strategy Michael Gilster – Business Administration Dr. Markus Rudolph – Marketing & Sales International Business Dr. Aldo Ammendola – Research & Development
Number of employed	> 250 employees in Heppenheim; >100 employees in Berlin, 6 employees in Vienna, >20 employees in Milano
Revenue	~ 250 Mio. Euros (2022)
Annual growth rate	~ 15 %
International	Export to > 30 countries, main target area is Europe
Products	> 130 (OTC and 77 prescription-only pharmaceuticals) medicinal products, medical devices and cosmetics
Market leader Germany	Pediatrics
Subsidiaries	Pädia GmbH, >25 OTC products for children www.paedia.de Beyvers GmbH, CMO for liquids and semi-liquids in Berlin www.beyvers.de/

Branches	Vienna, Austria – www.infectopharm.at Milano, Italy – www.infectopharm.it
Awards	1,000 Companies to Inspire Europe (LSEG), Most Crisis-Proof Employer (Creditreform), Golden Tablet, Most Innovative Product, Best Pharmaceutical Company (Pharma Trend Deutschland), Innovator of the Year (Statista & Capital), Germany's Best (Focus Money), Green Champion (F.A.Z.-Institut)

Last update: 05.2023

About InfectoPharm

InfectoPharm Arzneimittel und Consilium GmbH is a medium-sized family-led German company focusing on the fields of pediatrics, dermatology, HNO and unique antibiotic treatment options. For 35 years, InfectoPharm has distinguished itself as a groundbreaking pioneer in various fields of indications. The portfolio currently comprises around 130 preparations with numerous innovations in the fields of pediatrics, dermatology, infectious diseases, pneumology and allergology, which are increasingly attracting international attention. The "consilium service" is available free of charge to specialists as a product-neutral advisory and knowledge transfer service.

The InfectoPharm Group is engaged in more than 30 international partnerships and is increasingly expanding into non-EU markets. Subsidiaries of the group in Austria and Italy operate with a selected part of the portfolio. The InfectoPharm Group further consists of two strategically matching German subsidiaries: Pädia GmbH offers a distinct pediatric OTC portfolio with about 27 prescription-free pharmaceuticals and Beyvers GmbH in Berlin is an internationally known full service-supplier for pharmaceuticals and cosmetics.

With more than 350 employees, the group generates annual sales of around 250 million euros (2022) and an average growth rate of 15 percent. InfectoPharm regularly receives awards from the medical profession, such as the "Golden Tablet" or currently as "Most Crisis-Proof Employer" from Creditreform.